Last 35 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -339.29 | 25.86 | 123.40 | 77.43 | — | — | — | — | 63.56 | — | — | — | — | 4.85 | — | 17.63 | — | — | — | 26.81 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -34.3% | — | — | — | — | — | |
| P/S Ratio | 19.76 | 7.89 | 8.02 | 5.35 | 6.51 | 5.06 | 5.05 | 7.47 | 3.86 | 2.34 | 3.03 | 3.85 | 3.82 | 1.89 | 4.63 | 2.13 | 4.14 | 2.24 | 12.67 | 4.57 | 41.09 |
| — | +56.0% | +58.9% | -28.5% | +68.6% | +116.6% | +66.5% | +93.9% | +1.1% | +23.7% | -34.5% | +80.8% | -7.8% | -15.5% | -63.5% | -53.4% | -89.9% | -82.3% | +210.4% | -99.2% | — | |
| P/B Ratio | 59.34 | 25.48 | 25.43 | 17.40 | 25.27 | 15.99 | 14.27 | 14.25 | 9.97 | 6.30 | 6.24 | 7.28 | 6.35 | 5.42 | 8.74 | 5.54 | 4.76 | 4.97 | 8.24 | 6.32 | 8.13 |
| — | +59.3% | +78.2% | +22.1% | +153.5% | +153.9% | +128.9% | +95.6% | +57.0% | +16.2% | -28.7% | +31.5% | +33.3% | +9.1% | +6.1% | -12.3% | -41.4% | -33.6% | -8.6% | -48.9% | -93.2% | |
| P/FCF | 155.04 | 40.87 | 26.55 | — | 12.44 | 12.04 | 41.74 | — | 13.49 | 16.89 | — | — | 30.71 | 3.19 | — | 6.40 | — | 9.68 | 22.83 | — | — |
| — | +239.5% | -36.4% | — | -7.8% | -28.7% | — | — | -56.1% | +429.3% | — | — | — | -67.0% | — | — | — | — | +74.6% | — | — | |
| EV / EBITDA | 385.10 | 23.23 | 54.38 | 31.48 | — | — | 166.54 | 92.27 | 45.54 | — | — | — | — | 4.64 | — | 11.92 | — | — | — | 17.86 | — |
| — | — | -67.3% | -65.9% | — | — | — | — | — | — | — | — | — | — | — | -33.2% | — | — | — | — | — | |
| EV / EBIT | 9999.00 | 23.23 | 262.66 | 41.79 | — | — | — | — | 70.42 | — | — | — | — | 4.02 | — | 14.75 | — | — | — | 19.72 | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -25.2% | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 53.5% | 67.6% | 60.7% | 61.6% | 35.0% | 63.0% | 57.1% | 55.6% | 61.0% | 62.0% | 62.9% | 49.6% | 62.6% | 80.7% | 63.1% | 74.8% | 62.7% | 62.7% | 67.0% | 95.4% | 20.4% |
| — | +7.3% | +6.4% | +10.7% | -42.7% | +1.6% | -9.2% | +12.0% | -2.6% | -23.2% | -0.4% | -33.7% | -0.1% | +28.7% | -5.8% | -21.6% | +207.5% | -34.4% | -22.7% | +135.3% | +93.1% | |
| Operating Margin | 0.1% | 34.0% | 9.9% | 11.6% | -6.1% | -7.8% | -2.7% | 5.4% | 4.9% | -32.3% | -10.0% | -27.3% | -7.8% | 32.4% | -47.8% | 12.5% | -89.9% | -18.2% | -233.8% | 21.6% | -754.5% |
| — | +536.8% | +465.8% | +114.4% | -223.1% | +75.9% | +72.9% | +119.8% | +163.2% | -199.9% | +79.0% | -318.1% | +91.3% | +277.7% | +79.6% | -42.1% | +88.1% | +76.0% | -618.6% | +100.2% | -119.4% | |
| Net Margin | -5.8% | 30.8% | 6.4% | 7.0% | -8.6% | -13.7% | -9.1% | -5.1% | 6.1% | -33.5% | -10.2% | -30.8% | -8.2% | 38.0% | -50.2% | 10.7% | -94.6% | -21.2% | -244.9% | 17.1% | -786.3% |
| — | +325.5% | +170.4% | +235.7% | -241.3% | +59.2% | +10.7% | +83.4% | +173.7% | -188.2% | +79.7% | -387.5% | +91.3% | +279.5% | +79.5% | -37.1% | +88.0% | +67.8% | -669.6% | +100.2% | -119.5% |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -18.2% | 30.0% | 5.5% | 6.0% | -8.2% | -10.7% | -6.4% | -3.0% | 4.3% | -21.0% | -5.2% | -13.9% | -3.4% | 32.6% | -21.9% | 7.5% | -24.9% | -11.7% | -34.4% | 6.2% | -33.5% |
| — | +380.9% | +185.1% | +303.4% | -292.2% | +49.2% | -22.8% | +78.8% | +223.6% | -164.4% | +76.1% | -285.4% | +86.2% | +378.6% | +36.4% | +20.5% | +25.5% | -22.8% | -225.0% | +106.9% | +78.3% | |
| ROA | -5.5% | 10.8% | 1.6% | 1.5% | -1.9% | -2.8% | -2.0% | -1.1% | 1.9% | -9.7% | -2.6% | -7.1% | -1.9% | 16.6% | -10.9% | 3.9% | -13.7% | -6.7% | -21.0% | 3.8% | -21.6% |
| — | +489.6% | +183.4% | +241.2% | -200.9% | +71.3% | +24.3% | +85.0% | +200.0% | -158.4% | +76.1% | -282.0% | +86.4% | +346.6% | +48.4% | +2.0% | +36.6% | -2.1% | -218.3% | +109.4% | +57.0% | |
| ROIC | 0.2% | 26.7% | 11.1% | 19.5% | -11.0% | -3.3% | -0.9% | 2.4% | 110.5% | -95.9% | -34.4% | -2033.7% | -42.8% | 132.9% | -59.7% | 21.3% | -64.4% | -28.6% | -53.0% | 20.6% | -637.4% |
| — | +901.2% | +1305.6% | +718.4% | -110.0% | +96.5% | +97.3% | +100.1% | +358.2% | -172.2% | +42.4% | -9656.9% | +33.6% | +565.2% | -12.8% | +3.1% | +89.9% | +56.2% | -133.7% | +104.8% | -87.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 | Q1 '23 | Q4 '22 | Q3 '22 | Q2 '22 | Q1 '22 | Q4 '21 | Q3 '21 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.19 | 0.62 | 0.40 | 0.35 | 0.14 | 1.28 | 1.23 | 1.23 | 0.27 | 0.36 | 0.33 | 0.35 | 0.34 | 0.37 | 0.58 | 0.50 | 0.57 | 0.48 | 0.47 | 0.38 | 0.43 |
| — | -51.4% | -67.6% | -71.2% | -48.0% | +253.3% | +274.2% | +248.4% | -20.9% | -1.6% | -43.3% | -29.3% | -40.1% | -23.3% | +22.8% | +31.4% | +33.9% | +46.1% | +42.5% | -16.7% | -91.6% | |
| Debt / EBITDA | 7.54 | 2.27 | 3.46 | 2.66 | — | — | 55.54 | 30.48 | 5.50 | — | — | — | — | 1.52 | — | 4.96 | — | — | — | 4.61 | — |
| — | — | -93.8% | -91.3% | — | — | — | — | — | — | — | — | — | — | — | +7.6% | — | — | — | — | — | |
| Current Ratio | 1.57 | 1.52 | 1.21 | 1.57 | 1.63 | 1.77 | 1.97 | 2.06 | 1.51 | 1.40 | 1.59 | 1.65 | 2.61 | 2.75 | 2.55 | 3.10 | 3.52 | 5.19 | 5.39 | 5.18 | 4.83 |
| — | -14.3% | -38.8% | -23.5% | +8.1% | +27.0% | +24.3% | +24.4% | -42.3% | -49.2% | -37.8% | -46.6% | -25.8% | -47.1% | -52.6% | -40.2% | -27.0% | -44.6% | -43.1% | -20.5% | +58.7% | |
| Quick Ratio | 1.17 | 1.30 | 0.88 | 1.17 | 1.25 | 1.16 | 1.43 | 1.29 | 1.41 | 1.28 | 1.43 | 1.60 | 2.51 | 2.66 | 2.49 | 3.01 | 3.42 | 5.05 | 5.24 | 5.06 | 4.76 |
| — | +12.0% | -38.8% | -9.2% | -11.4% | -9.8% | -0.1% | -19.0% | -43.9% | -51.8% | -42.5% | -47.0% | -26.5% | -47.3% | -52.4% | -40.5% | -28.2% | -43.7% | -42.1% | -18.2% | +89.6% | |
| Interest Coverage | 0.05 | 11.89 | 0.87 | 2.17 | -0.61 | -1.10 | -0.29 | -0.38 | 63.63 | -56.44 | -72.73 | -7.74 | -17.68 | 37.77 | -20.11 | 4.15 | -19.30 | -6.15 | -20.93 | 4.78 | -23.67 |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying ETON stock.
Eton Pharmaceuticals, Inc.'s current P/E is -339.3x. The average P/E over the last 3 quarters is 75.6x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Eton Pharmaceuticals, Inc.'s current operating margin is 0.1%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Eton Pharmaceuticals, Inc.'s business trajectory between earnings reports.